ASCO24 CAR-T round-up @ ASCO24

This year's CAR-T updates at ASCO24 mostly featured longer follow up and subgroup analyses from existing trials. Most noteworthy was the longer follow up from one of our life sciences top picks Autolus, which led to excitement in the room and an approx. 9% stock move. The company presented a 40% ongoing remission rate without subsequent therapy at median follow up of 21 months for obe-cel (CD19 CAR-T) in r/r adult ALL. On top of the well-established safety profile, we think this efficacy outcome sets the candidate up for a strong launch in 2025 (PDUFA 16 November 2024). Beyond that, Kite/Gilead posted a 40% OS rate at 48 months with Tecartus (CD19 CAR-T), also in r/r adult ALL, Legend/J&J presented Carvykti subgroup analysis in MM, BMS presented 3 datasets for Breyanzi (CD19 CAR-T) including longer follow up in r/r LBCL, and subgroup analysis in MCL and FL, and AstraZeneca reported an ORR of 56.5% for its GPC3 targeting CAR-T in advanced HCC.